Previous 10 | Next 10 |
home / stock / aktx / aktx articles
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapi...
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing advanced therapies...
Prioritization of Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy, a disabling ophth...
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to ...
BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanc...
NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing adva...
NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing adva...
MIAMI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the ...
MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emer...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...